Unknown direct molecular target

The term "Unknown direct molecular target" is a pharmacological classification used when a drug demonstrates therapeutic efficacy, but its specific binding partner—such as a protein, enzyme, or receptor—has not been identified (NCBI Bookshelf, 2021). This scenario is common in phenotypic drug discovery, where compounds are screened for their ability to alter a disease-relevant biological process rather than their affinity for a pre-selected target (AZoLifeSciences, 2022). While many historically significant drugs, including certain anesthetics and antiepileptics, were used for decades without a known target, the lack of molecular clarity poses significant hurdles for modern drug development (NCBI Bookshelf, 2021). Specifically, it complicates structure-based optimization, the prediction of off-target toxicities, and the development of companion diagnostics (Receptor.AI, 2023). Identifying these "orphan" targets is a major focus of chemical proteomics and reverse pharmacology, as elucidating the mechanism can lead to more potent and safer therapeutic derivatives (AZoLifeSciences, 2022). Ultimately, a drug with an unknown target remains a challenge for precision medicine until its molecular interactions are fully mapped.

Other names

Unidentified targetUndisclosed mechanismOrphan targetPhenotypic target

The mechanism of action is unknown or has not been characterized at the molecular level.